{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T10:16:22Z","timestamp":1649067382951},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"AstraZeneca"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Regulatory Toxicology and Pharmacology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.yrtph.2015.06.020","type":"journal-article","created":{"date-parts":[[2015,7,8]],"date-time":"2015-07-08T18:44:49Z","timestamp":1436381089000},"page":"227-231","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Net gain analysis, an addition to responder analysis \u2013 The case of antipsychotic treatment of acute mania"],"prefix":"10.1016","volume":"73","author":[{"given":"C.C.M.","family":"Welten","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.W.J.","family":"Koeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.D.","family":"Wohlfarth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.G.","family":"Storosum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.C.","family":"Gispen-de Wied","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.G.M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.A.J.P.","family":"Denys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yrtph.2015.06.020_bib1","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/sim.1687","article-title":"Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses","volume":"23","author":"Austin","year":"2004","journal-title":"Statistics Med."},{"issue":"1\u20132","key":"10.1016\/j.yrtph.2015.06.020_bib2","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0165-0327(02)00335-X","article-title":"Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania","volume":"73","author":"Baker","year":"2003","journal-title":"J.\u00a0Affect. Disord."},{"issue":"5","key":"10.1016\/j.yrtph.2015.06.020_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.euroneuro.2009.01.012","article-title":"Committee for medicinal products for human use (CHMP) assessment on efficacy of antidepressants","volume":"19","author":"Broich","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.yrtph.2015.06.020_bib4","series-title":"Note for Guidance on Clinical Investigation of Medicinal Product of the Treatment and Prevention of Bipolar Disorder. (EMA\/CPMP\/EWP\/567\/98\/2001.)","author":"CHMP","year":"2001"},{"key":"10.1016\/j.yrtph.2015.06.020_bib5","series-title":"Guideline on the Choice of the Non-inferiority Margin. (EMEA\/CPMP\/EWP\/2158\/99)","author":"CHMP","year":"2005"},{"key":"10.1016\/j.yrtph.2015.06.020_bib6","series-title":"Guideline on Clinical Investigation of Medicinal Products Indicated for the Treatment of Social Anxiety Disorder (SAD)","author":"CHMP","year":"2006"},{"key":"10.1016\/j.yrtph.2015.06.020_bib7","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.yrtph.2015.06.020_bib8","series-title":"Guidance for Industry Patient-reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims","author":"FDA","year":"2009"},{"issue":"346","key":"10.1016\/j.yrtph.2015.06.020_bib9","article-title":"Evidence-based guidelines for treating bipolar disorder: revised second edition \u2013 recommendations from the British Association for psychopharmacology","volume":"23","author":"Goodwin","year":"2009","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.yrtph.2015.06.020_bib10","series-title":"Harmonized Tripartite Guideline Statistical Principles for Clinical Trials: E9","author":"ICH","year":"1998"},{"key":"10.1016\/j.yrtph.2015.06.020_bib11","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1183\/09031936.02.00063702","article-title":"Interpreting thresholds for a clinically significant change in health status in asthma and COPD","volume":"19","author":"Jones","year":"2002","journal-title":"Eur. Respir. J."},{"issue":"10","key":"10.1016\/j.yrtph.2015.06.020_bib12","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1002\/sim.5634","article-title":"Assessment of statistical significance and clinical relevance","volume":"32","author":"Kieser","year":"2013","journal-title":"Statistics Med."},{"key":"10.1016\/j.yrtph.2015.06.020_bib13","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1002\/sim.1910","article-title":"Power and sample size determination when assessing the clinical relevance of trial results by \u2018responder analyses\u2019","volume":"23","author":"Kieser","year":"2004","journal-title":"Statistics Med."},{"issue":"4","key":"10.1016\/j.yrtph.2015.06.020_bib14","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4088\/JCP.v67n0401","article-title":"Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials","volume":"67","author":"Perlis","year":"2006","journal-title":"J.\u00a0Clin. Psychiatry"},{"key":"10.1016\/j.yrtph.2015.06.020_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/sim.2331","article-title":"Dichotomizing continuous predictors in multiple regression: a bad idea","volume":"25","author":"Royston","year":"2006","journal-title":"Statistics Med."},{"issue":"4","key":"10.1016\/j.yrtph.2015.06.020_bib16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archpsyc.64.4.442","article-title":"Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials","volume":"64","author":"Scherk","year":"2007","journal-title":"Arch. General Psychiatry"},{"key":"10.1016\/j.yrtph.2015.06.020_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/pst.90","article-title":"Disappointing dichotomies","volume":"2","author":"Senn","year":"2003","journal-title":"Pharm. Stat."},{"key":"10.1016\/j.yrtph.2015.06.020_bib18","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1002\/sim.3603","article-title":"Measurement in clinical trials: a neglected issue for statisticians?","volume":"28","author":"Senn","year":"2009","journal-title":"Statistics Med."},{"key":"10.1016\/j.yrtph.2015.06.020_bib19","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1399-5618.2007.00468.x","article-title":"Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials","volume":"9","author":"Smith","year":"2007","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.yrtph.2015.06.020_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1745-6215-8-31","article-title":"Responder analyses and the assessment of a clinically relevant treatment effect","volume":"8","author":"Snapinn","year":"2007","journal-title":"Trials"},{"key":"10.1016\/j.yrtph.2015.06.020_bib21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1017\/S1461145709991246","article-title":"Level of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis","volume":"13","author":"Tamayo","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.yrtph.2015.06.020_bib22","article-title":"Responder analyses\u2014a PhRMA position paper","volume":"3","author":"Uryniak","year":"2011","journal-title":"Am. Statistical Assoc. Statistics Biopharm."},{"key":"10.1016\/j.yrtph.2015.06.020_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-0038-1635499","article-title":"Clinically relevant differences and shifted null hypotheses","volume":"26","author":"Victor","year":"1987","journal-title":"Methods Info. Med."},{"key":"10.1016\/j.yrtph.2015.06.020_bib24","volume":"vol. 59","author":"Wolf","year":"1986"},{"key":"10.1016\/j.yrtph.2015.06.020_bib25","first-page":"1","article-title":"A\u00a0network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania","volume":"18","author":"Yildiz","year":"2014","journal-title":"Psychol. Med."},{"issue":"7","key":"10.1016\/j.yrtph.2015.06.020_bib26","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1017\/S1461145710001641","article-title":"Factors modifying drug and placebo responses in randomized trials for bipolar mania","volume":"14","author":"Yildiz","year":"2011","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.yrtph.2015.06.020_bib27","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A\u00a0rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Regulatory Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230015300076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0273230015300076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T12:56:34Z","timestamp":1589547394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0273230015300076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0273230015300076"],"URL":"https:\/\/doi.org\/10.1016\/j.yrtph.2015.06.020","relation":{},"ISSN":["0273-2300"],"issn-type":[{"value":"0273-2300","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Net gain analysis, an addition to responder analysis \u2013 The case of antipsychotic treatment of acute mania","name":"articletitle","label":"Article Title"},{"value":"Regulatory Toxicology and Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yrtph.2015.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}